Addex Therapeutics (ADXN) Projected to Post Earnings on Monday

Addex Therapeutics (NASDAQ:ADXN) is expected to post its H2 2025 results before the market opens on Monday, April 27th. Analysts expect Addex Therapeutics to post earnings of ($1.4246) per share and revenue of $0.2370 million for the quarter. Individuals can find conference call details on the company’s upcoming H2 2025 earning report page for the latest details on the call scheduled for Monday, April 27, 2026 at 3:00 AM ET.

Addex Therapeutics Stock Performance

ADXN stock opened at $6.75 on Monday. Addex Therapeutics has a fifty-two week low of $5.41 and a fifty-two week high of $12.05. The business’s 50 day moving average price is $6.82 and its two-hundred day moving average price is $7.82. The company has a market capitalization of $8.30 million, a price-to-earnings ratio of -1.18 and a beta of 1.48.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a report on Wednesday, April 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.